Characterization of the brain network architecture and its alterations in pathologies are essential for a better understanding of mechanisms of action in health and disease and paves the way for the development of targeted therapeutic strategies. In the field of demyelinating disorders, thyromimetic treatment provides a promising remyelinating strategy inducing oligodendrogenesis in vitro. We tested the potential of sobetirome (GC-1), a thyroid hormone analogue, to induce remyelination in vivo in the cuprizone demyelinated mouse model and we investigated its action on the resting state (rsfMRI) mouse brain functional connectivity.
This abstract and the presentation materials are available to members only; a login is required.